Skip to main content

Table 4 Dose reductions and attributed reasons for dose reductions of nal-IRI + 5-FU/LV

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Number of dose reductions N = 18 (%)
 1 15 (83)
 2 3 (17)
Reason attributed for dose
 Fatigue 8 (44)
 Diarrhea 8 (44)
 Nausea 2 (11)
 Neutropenia 2 (11)
 Anorexia 2 (11)
 Abdominal cramping 1 (6)
 Ageusia 1 (6)
 Not defined 1 (6)